Craig-Hallum initiated coverage of scPharmaceuticals with a Buy rating and $20 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCPH:
- scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- scPharmaceuticals reports Q2 EPS (35c), consensus (37c)
- SCPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
- scPharmaceuticals announces positive Type C feedback from FDA on FUROSCIX
